Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...
OXFORD, England, July 9, 2025 /PRNewswire/ -- A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, an AI-powered tool developed ...
An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in Oxford, England, is highly accurate in screening for cardiac amyloidosis, a ...
Clinicians can order the FDA-cleared echocardiography AI through IMVARIA's AI Lab Working with IMVARIA gives clinicians ...
AI-enhanced echocardiography demonstrates high diagnostic accuracy for detecting ATTR-CM and AL-CM, according to new clinical study findings.
A month after raising $55 million to advance its AI-enhanced ultrasound diagnostics for cardiovascular disease, Ultromics Ltd. presented strong results for its U.S. FDA-cleared AI analysis of ...
Cardiac amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins. These amyloids can gather in different organs throughout the body, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results